sciencenewsnet.in

Yale Cancer Center Expert Reports Significant Improvement in Survival for Lung Cancer Patients in the ADAURA Phase III Trial, involving AstraZeneca’s Targeted Therapy Drug, Tagrisso

March 9, 2023 sarah JonasExpert Pitch

New data released from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a significant improvement in overall survival, compared to placebo in the adjuvant treatment of patients with early stage EGFR-mutated lung cancer. Roy S. Herbst, MD, PhD, deputy…

Pfizer-BioNTech and AstraZeneca vaccines offer high protection against severe COVID-19, 6 months after second doses, finds study of over 7 million adults

July 20, 2022 sarah JonasResearch Results

Protection against severe COVID-19 by two doses of Pfizer-BioNTech and AstraZeneca COVID-19 vaccines remained high up to six months after second doses, finds new research which analysed NHS health record data on over seven million adults. Reassuringly, the University of Bristol-led study published in The BMJ today [July 20], found protection in older adults aged over 65 years, and in clinically vulnerable adults.

LJI scientists publish first head-to-head comparison of four COVID-19 vaccines

May 31, 2022 sarah JonasResearch Results

“Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”

Yale study leads to FDA approval of drug to treat non-small cell lung cancer

December 18, 2020 sarah JonasResearch Results

Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.